They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Trescal provides precision calibration expertise in every industry, geography and instrument across the world
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Up to 100 million mRNA vaccine doses could be produced in Australia each year
It is a novel oral NLRP3 inflammasome inhibitor
The company plans to expand its portfolio in regulated markets aggressively
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Subscribe To Our Newsletter & Stay Updated
